Press Releases April 8, 2026 08:00 PM

The Oncology Institute to Participate in the 25th Annual Needham Healthcare Conference

The Oncology Institute Announces Participation in the 25th Annual Needham Healthcare Conference

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
TOI

The Oncology Institute, Inc. (NASDAQ: TOI), a leading value-based oncology care provider, will participate virtually in the 25th Annual Needham Healthcare Conference. CEO Dr. Daniel Virnich and CFO Rob Carter will host a fireside chat to discuss the company's operations and growth strategies, accessible via webcast on April 15, 2026.

The Oncology Institute to Participate in the 25th Annual Needham Healthcare Conference
TOI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The Oncology Institute is one of the largest value-based oncology groups in the U.S., serving approximately 1.9 million patients.
  • The company operates over 100 clinics and affiliate locations across five states with more than 180 employed and affiliate clinicians.
  • Participation in the Needham Healthcare Conference provides an opportunity to highlight its cutting-edge, evidence-based cancer care and discuss future growth plans.

CERRITOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the 25th Annual Needham Healthcare Conference, being held virtually on Wednesday, April 15, 2026, including a fireside chat at 3:45 p.m. ET.

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

About The Oncology Institute (www.theoncologyinstitute.com):

Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.

Media
The Oncology Institute, Inc.
[email protected]

Investors
ICR Healthcare
[email protected]


Risks

  • Market and regulatory changes impacting value-based oncology care reimbursement and operations.
  • Competition in oncology care delivery from other established healthcare providers and novel treatment approaches.
  • Execution risk related to expansion plans and ability to maintain quality care across multiple locations.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026